Kiora Pharmaceuticals receives grant to fund novel clinical trial endpoints for inherited retinal diseases

4d ago, source: ophthalmologytimes

According to the company, the grant funding from the Choroideremia Research Foundation is in support of validating functional ...

KPRX Kiora Pharmaceuticals, Inc.

27d ago, source: Seeking Alpha

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead ...

Why Is Kiora Pharmaceuticals (KPRX) Stock Down 49% Today?

10mon ago, source: Hosted on MSN

Kiora Pharmaceuticals (NASDAQ ... Ladenburg Thalmann & Co. Inc., the sole book-running manager of the offering, has 45 days to exercise this option. Investors aren’t handling the stock offering ...

Kiora Pharmaceuticals Stock (NASDAQ:KPRX), Analyst Ratings, Price Targets, Predictions

5mon ago, source: Benzinga.com

Kiora Pharmaceuticals Inc has a consensus price target of $31.38, established from looking at the 17 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC ...

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

23d ago, source: Stockhouse

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or ...

Kiora Pharmaceuticals Inc KPRX

24d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

23d ago, source: The Globe and Mail

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX ...

Kiora Pharmaceuticals, Inc. (KPRX)

1y ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

Kiora Pharmaceuticals Inc.

1y ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

KPRX Kiora Pharmaceuticals, Inc.

26d ago, source: Seeking Alpha

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.

Kiora Pharmaceuticals Inc (KPRX)

1mon ago, source: Investing

At the close in NYSE,... Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United ...